A randomized double - blind placebo - controlled cross - over trial of the impact on quality of life of continuing dexamethasone beyond 24   h following <font color="red">adjuvant_2</font> <font color="red">chemotherapy_2</font> <font color="red">for_2</font> <font color="red">breast_2</font> <font color="red">cancer_2</font> <font color="red">._2</font> 
<br>
<br> Uncertainty remains about the optimal anti - emetic regimen for control of delayed nausea and vomiting after <font color="red">adjuvant_2</font> <font color="red">chemotherapy_2</font> <font color="red">for_2</font> <font color="red">breast_2</font> <font color="red">cancer_2</font> <font color="red">._2</font> Many patients receive dexamethasone but complain of insomnia , anxiety / agitation , and indigestion . The aim was to determine if <font color="red">patients_2</font> <font color="red">receiving_2</font> <font color="red">chemotherapy_2</font> <font color="red">for_2</font> <font color="red">breast_2</font> <font color="red">cancer_2</font> prefer treatment with dexamethasone or placebo for prophylaxis against delayed nausea and vomiting , and to compare quality of life ( QOL ) between the two treatments . In this randomized , double - blind , cross - over trial , we compared oral dexamethasone ( 4   mg twice daily for 2   days ) versus placebo for <font color="red">chemotherapy_1</font> <font color="red">-_1</font> <font color="red">naïve_1</font> <font color="red">patients_1</font> <font color="red">with_1</font> <font color="red">breast_1</font> <font color="red">cancer_1</font> <font color="red">._1</font> All patients received intravenous granisetron and dexamethasone pre - chemotherapy and oral granisetron on day 2 . Primary endpoints were : ( i ) patient preference ; ( ii ) difference between cycles in change of QOL from days 1 to 8 . <font color="red">Median_2</font> <font color="red">age_2</font> <font color="red">of_2</font> <font color="red">the_2</font> <font color="red">94_2</font> <font color="red">women_2</font> <font color="red">was_2</font> <font color="red">51_2</font> <font color="red"> _2</font> <font color="red">years_2</font> <font color="red">(_2</font> <font color="red">range_2</font> <font color="red">27_2</font> <font color="red">-_2</font> <font color="red">76_2</font> <font color="red">)_2</font> <font color="red">:_2</font> 79 received fluorouracil / epirubicin / cyclophosphamide and 15 received doxorubicin / cyclophosphamide . <font color="red">Thirteen_1</font> <font color="red">withdrew_1</font> <font color="red">pre_1</font> <font color="red">-_1</font> <font color="red">cycle_1</font> <font color="red">2_1</font> with no differences between arms . Of 80 patients stating a preference , 31 preferred placebo ( 39   % , 95   % CI : 28 - 50   % ) and 37 ( 46   % , 95   % CI : 35 - 58   % ) preferred dexamethasone ; 12 had no preference . There were no differences in intensity of vomiting , nausea , or time to onset of vomiting . There was greater decrease in global QOL ( p   =   0.06 ) when patients received dexamethasone . No other symptom / QOL domains differed significantly . In conclusion , no significant difference was found in patient preference , QOL , or symptoms regardless of whether dexamethasone or placebo was used after <font color="red">adjuvant_2</font> <font color="red">chemotherapy_2</font> <font color="red">._2</font>